Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

By P. Mease, B. Goffe, J. Metz, A. VanderStoep, B. Finck, D. Burge. The Lancet, 2000

1,420 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/e39b8ea16b9cc672dffd14a531a5ea102d3f1723

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

M. Lebwohl

Citations in the corpus

Mechanisms of TNF-α– and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis (2003, positive): “Perhaps the most convincing evidence stems from clinical trials showing that TNF blockade dramatically ameliorates psoriatic joint pain and swelling; this evidence led to the Food and Drug Administration’s first approval of a drug, etanercept, for treatment of PsA (36, 37).”
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. (2008, methodology): “In PsA clinical trials a 78 tender and 76 swollen joint count is frequently used to accommodate the commonly involved DIP and carpal-metacarpal joints.(17) The DAS scoring system uses a weighted mathematic formula, derived from clinical trials in RA.”
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. (2012, methodology): “Examples d ‘‘Proportions of patients responding were compared between treatment groups with the Mantel-Haenszel c 2 test, adjusted for the stratiﬁcation variable, methotrexate use’’[103].”
Etanercept as monotherapy in patients with psoriasis. (2003, neutral): “Headache 11 (7) 5 (3) 19 (12) 11 (7) 11 (7) 8 (5) 8 (5) 20 (12) 14 (9)”
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial (2005, background): “Some of the current treatments for PsA, including sulfasalazine (19), leflunomide (33), and etanercept (8, 9) have been well assessed; many of the other commonly used therapies have been adapted from treatment of RA and their use in PsA is not supported by clinical trial data.”
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration (2001, methodology): “Each vial was reconstituted with 1 mL bacteriostatic water for injection (80).”
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) (2004, neutral): “Upper respiratory infection 80 (26) 86 (28) 93 (30) Diarrhea 49 (16) 52 (17) 57 (19) Headache 36 (12) 45 (15) 35 (11) Flu syndrome 37 (12) 37 (12) 38 (12) Injection-site reaction† 16 (5) 55 (18) 62 (20) Anemia† 8 (3) 23 (8) 17 (6) Chest pain 37 (12) 42 (14) 56 (18) Abdominal pain 24 (8) 25 ( 8 ) 29 ”